Wynzora
Plaque Psoriasis
Key Facts
About Almirall
Almirall is a publicly traded, revenue-generating pharmaceutical company with a singular strategic focus on becoming a global leader in medical dermatology. The company has successfully transformed from a broad-based pharma player into a specialized dermatology entity, leveraging deep internal R&D, strategic partnerships, and a direct commercial infrastructure. Its mission is to deliver innovative science to improve the lives of patients with skin conditions, supported by a growing portfolio of marketed products and a promising clinical pipeline.
View full company profileTherapeutic Areas
Other Plaque Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| Piclidenoson (CF101) | Can Fite Biopharma | Phase III |
| Psoriasis Trial | Clinical Investigation Specialists | Not Specified |
| ZL-1102 (CB001) | Crescendo Biologics | Phase 2 |
| AX-158 | Artax Biopharma | Phase 2 |
| JNJ-2113 | Johnson & Johnson | Phase 3 |
| VTAMA® (tapinarof) | Roivant Sciences | Approved |
| JNJ-81201887 (via Janssen) | OmniAb | Approved |